West Offers Patients Even More Oncology Treatment Options

MEMPHIS, Tenn., Oct. 22, 2020 /PRNewswire-PRWeb/ — As an affiliate of OneOncology, West Cancer Center & Research Institute now has the ability to further its clinical trial offerings and oncology research knowledge by joining the launch of OneR.

OneR is a new, unprecedented technology platform and collaboration throughout the OneOncology network that provides seamless clinical trial management, increased access to trial therapies for patients, and more oncology research information readily available to our clinicians. Patients can participate in clinical trials for specific cancer types, in an effort to decrease side effects of current treatments, or with aims to improve disease outcomes – and now, with the implementation of OneR, these efforts are supported more than ever before.

Mitch Graves, CEO of West Cancer Center states, “We are incredibly excited to join the launch of OneR! This new platform allows us to offer more clinical trials to patients in need by centralizing business functions, regulatory submissions, and clinical trial matching technology while also maintaining our flexibility to participate in other clinical trial initiatives managed by our in-house Clinical Research Department. It’s an exciting time for cancer research, and this new initiative will give our patients and their families more treatment options than ever before!”

Recently, West added “Research Institute” to its name to ensure the priority and focus it has on clinical research was made apparent and embedded into its culture. This new opportunity only further promotes its many initiatives to increase oncology research across the globe.

 

SOURCE West Cancer Center

Staff

Recent Posts

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

29 minutes ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

1 hour ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

15 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

18 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

18 hours ago